Sterile injectables are the lifeline of modern healthcare — from anaesthetics in surgery to antibiotics in intensive care. Demand for these critical medicines is rising sharply in historically underfunded and underinvested markets, but local manufacturing capacity has not kept pace.
For Vishal Wagh, Marketing Director of Adam Fabriwerk, this shouldn’t be the story in the year 2025. “What we do in this moment matters. We want to help close this gap so local companies can build self-reliance.” This conviction is shaped not by markets alone. It is rooted in experience. During the pandemic, shortages of sterile injectables like propofol and basic antibiotics cost lives.
Life Sciences is a vast industry. And Adam Fabriwerk has focused all its attention on a specific niche — designing and manufacturing reliable world-class sterile processing skids and vessels. For our readers outside the biopharma spectrum, the company designs and builds the stainless-steel “backbone” of sterile drug production. Its skids are self-contained processing units — compact systems of tanks, pumps, pipes, and controls that prepare medicines under tightly controlled, contamination-free conditions. Its vessels are sterile storage tanks that hold sensitive liquids such as vaccines, antibiotics, or infusion solutions until they are filled into vials or syringes. Adam Fabriwerk doesn’t make the drugs themselves, but manufactures the critical infrastructure that ensures those drugs can be produced safely, consistently, and at scale. Vishal believes this responsibility doesn’t allow for shortcuts. “We’re not just making machines. We’re enabling life-saving therapies.”
precision as trust
Vishal describes his career as an intersection between engineering and healthcare. Fascinated early on by how technology could solve real-world problems, he gravitated to industries with direct human impact. Marketing pharmaceutical equipment allowed him to merge technical innovation with patient outcomes.
When you ask him what core skill sets are needed in his role, he doesn’t hesitate. Listening, he says, is how trust is built. “That discipline has stayed central. If you listen well enough, clients will tell you exactly what matters most to them.”
For Vishal, trust has become synonymous with sterile injectable manufacturing. Every vessel and skid that his company makes represents confidence — for regulators and pharma partners, and ultimately for patients. “Our business only grows when our clients succeed in delivering quality medicines at scale. The two are inseparable.”
This clarity has shaped a number of decisions at Adam Fabriwerk. Shifting focus to automation and digital compliance (like 21 CFR Part 11 and data integrity) required significant investment. “But it was necessary. If we want to be long-term partners in sterile manufacturing, we must be future-ready.”
the storyteller and the machine
Early in his career, he believed good technology sold itself. Now, he sees that even the best systems need a compelling narrative. Not hype. A clear line between what a machine does and the human lives it affects. To the uninitiated, a skid might look like a maze of polished steel and valves. But in reality, it is the unseen hero of injectable medicine. It keeps injectable solutions sterile by controlling every detail: the water used, the temperature maintained, and the cleaning cycles automated. The digital records prove compliance. “If the equipment is wrong, the medicine is unsafe.” That’s why he says storytelling matters in a field dominated by specifications, compliance protocols, and audits. “To take something as technical as process skids and show that these machines are not just hardware, but lifelines is nothing short of a craft.”
betting on the right markets
One decision that tested his conviction was the push into emerging markets. At the time, many doubted the move. The risks seemed too high: regulatory complexity, unpredictable demand, uneven infrastructure.
“People thought it was reckless,” he recalls. “But we believed these were the regions where sterile capacity mattered most — where our presence could make the biggest difference.”
Years later, those markets have become the fastest growing, and Adam Fabriwerk’s early presence has positioned the company as a trusted partner. It taught Vishal that persistence and optimism are skills in their own right. “My colleagues would probably say I bring both,” he admits with a smile.
beyond the call
Some beliefs have shifted over the years. Rigidity, Vishal realised, can be a weakness. He learned that the hard way. “If our equipment isn’t 100% right, it doesn’t ship,” he says flatly. “That’s the principle we hold onto when pressure is high, because the cost of failure in healthcare is measured in human lives.”
Patience has also become a lesson learned outside the classroom. Pharma projects often stretch across years, testing endurance as much as expertise.
The only way through, he says, is preparation: never walking into a client meeting without being thoroughly briefed, never letting deadlines erode standards.
For all the expertise Adam Fabriwerk brings, Vishal says his greatest lessons have come from his clients. “Every project teaches us something about balancing precision with reality,” he says. Some of those lessons came the hard way — like taking on aggressive timelines for first-time clients. “It taught us to overcommunicate, to manage expectations, not just deliver equipment.”
His most valuable learning came early: never compromise on quality. “That was drilled into me,” he says. “Because in this industry, compromise doesn’t just risk money. It risks people.”
invisible fingerprints
Vishal defines progress in personal terms. It is when sterile medicines are available in more regions, at lower cost, without compromising safety. In his own work, progress is measured by installations running reliably, by clients who return with confidence, and by knowing that systems designed and manufactured under his watch produce medicines that save lives.
He frames Adam Fabriwerk’s role in simple terms: the company may never be visible to patients, but its fingerprints are on every vial of sterile injectable that leaves a partner’s factory. “If you’ve ever received an IV antibiotic in a hospital, or an anaesthetic before surgery, chances are equipment like ours was involved somewhere in the process.”
The horizon excites him: integrating AI-driven monitoring into sterile systems to enable predictive assurance and zero downtime. “If we can anticipate issues before they happen, we can make sterile manufacturing even more reliable,” he says.
africa on my mind
That is also why Adam Fabriwerk is exhibiting at Pharmaconex 2025. For Vishal, the event is a strategic platform — a place where Africa’s biopharmaceutical ambitions of self-reliance in manufacturing are meeting their own moment. “For us, Pharmaconex is the ideal opportunity to signal our long-term commitment to the region’s healthcare future,” he says.
For visitors walking the floor at Pharmaconex in Cairo this year, the gleaming steel of an Adam Fabriwerk skid may be the first thing they notice. But Vishal hopes they also see the bigger picture: equipment as an enabler of trust and access in sterile medicines.
